Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 1.27% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.3 million (up 4.11% YoY), while the FY2025 annual figure was $8.3 million, up 12.75% from the prior year.
• Depreciation & Amortization (CF) steadied at $2.0 million in Q1 2026 per KYMR's latest filing, from $2.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q3 2025 and bottomed at $687000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 123.01% — and 2026, when it retreated 1.27%.
• Kymera Therapeutics' Depreciation & Amortization (CF) stood at $818000.0 in 2022, then climbed by 8.92% to $891000.0 in 2023, then jumped by 123.01% to $2.0 million in 2024, then increased by 2.26% to $2.0 million in 2025, then dropped by 0.49% to $2.0 million in 2026.
• Business Quant data shows KYMR's Depreciation & Amortization (CF) at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.